Last reviewed 2026-06-11 · How we verify

DLBCL arising from low-grade lymphoma — Treatment Landscape & Competitive Intelligence

DLBCL arising from low-grade lymphoma (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating DLBCL arising from low-grade lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. ADC Therapeutics SA · 1 drug in DLBCL arising from low-grade lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in DLBCL arising from low-grade lymphoma:

• DLBCL arising from low-grade lymphoma treatment updates — RSS
• DLBCL arising from low-grade lymphoma treatment updates — Atom
• DLBCL arising from low-grade lymphoma treatment updates — JSON

Cite this brief

Drug Landscape (2026). DLBCL arising from low-grade lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dlbcl-arising-from-low-grade-lymphoma. Accessed 2026-06-11.

Related

• DLBCL arising from low-grade lymphoma full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing